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A B S T R A C T
Oral administration is the most common route of drug delivery. The absorption of a drug from the gut into the
bloodstream involves disintegration of the solid dosage form, dissolution of the active pharmaceutical ingredient
and its transport across the gut wall. The eﬃciency of these processes is determined by highly complex and
dynamic interplay between the gastrointestinal tract, the dosage form and the API. The European Network on
Understanding Gastrointestinal Absorption-related Processes (UNGAP) aims to improve our understanding of
intestinal drug absorption by creating a multidisciplinary Network of researchers from academia and industry
engaging in scientiﬁc discussions. As part of the basis for the UNGAP project, this review aims to summarize the
current knowledge on anatomy and physiology of the human gastrointestinal tract with emphasis on human
studies for the evaluation of the regional drug absorption and the prediction of oral dosage form performance. A
range of factors and methods will be considered, including imaging methods, intraluminal sampling and, models
for predicting segmental/regional absorption. In addition, in vitro and in silico methods to evaluate regional
drug absorption will be discussed. This will provide the basis for further work on improving predictions for the in
vivo behavior of drug products in the gastrointestinal tract.
1. Introduction
The modern diet is extremely rich, well balanced in terms of di-
versity and energy dense. This would have represented a rare occur-
rence to our foraging and hunting ancestors – a banquet at every meal,
and as a consequence our bodies still function to make the most of the
occasion. This is achieved through controlled exposure of the intestine
to a preprocessed material and reduction by enzymes and motility to
ever simpler building blocks to be catalyzed and placed into other
metabolic pathways by the liver. Drugs, which are not nutrients (so-
called ‘anutrients’ or ‘xenobiotics’) are similarly exposed to these pro-
cesses. Regional specialization in anatomy and physiology is marked
along the gut in terms of ﬂuid composition, residence times, stirring and
the nature of the epithelium which has consequences for drug absorp-
tion. Active pharmaceutical ingredients vary greatly in their
physicochemical properties: speciﬁcally solubilities at diﬀerent pH and
diﬀerences in permeability across the epithelia along the gut. Therefore
presentation of drug at diﬀerent points during transit will yield diﬀer-
ences between formulations which are clinically important. In parti-
cular, the processing of food drives temporary changes in the en-
vironment which is why drug absorption has to be understood within a
nutritional sciences context.
The gastrointestinal (GI) tract consists of a series of connected
muscular tubes spanning from mouth to anus and its associated organs
including the liver, gallbladder and pancreas (Fig. 1). The beginning of
the digestion process is mastication. Chewing assists in an increasing
surface area of the food matrix, aiding swallowing by shaping a lu-
bricated bolus in the mouth. The oesophagus serves as a passage way
for the food bolus between the mouth and the stomach and is delineated
by the upper and the lower oesophageal sphincter. The lining of the:
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mouth and oesophagus, is composed of a surface layer stratiﬁed squa-
mous epithelium which is a toughened, thickened layer and not useful
for nutrient absorption.
Upon arrival of a bolus of food to the stomach, the proximal part of
the stomach or fundus relaxes in a process termed ‘receptive relaxation’
or ‘accommodation’. While the fundus functions as a storage organ, the
body or corpus and the distal part of the stomach or antrum are con-
cerned with mixing the food with acid, pepsin and gastric lipase as a
ﬁrst step in the digestion process. The stomach has a low pH which
reduces the bacterial bioburden and destroys some compounds that
could be harmful. Emesis assists with the expulsion of contaminated
food or poisons which could harm the body if entry to the systemic
circulation occurres. Thus, the upper parts of the gastrointestinal tract
do not have a role in direct nutrient absorption but serve to begin
processing of the matrix to a more water dispersed form. The lining of
these parts of the gut is squamous epithelium, transitioning to gastric
secretory epithelium in the stomach. The stomach stores food as a wet
solid/liquid and in combination with this the duodenum where an ab-
sorptive epithelium is encountered, begins to assess the nature and
nutritive value of the meal. This allows emptying at the rate appropriate
to the calorie content, allowing the other parts of the intestine, the
jejunum and ileum, to process gastric chyme in an orderly controlled
fashion. Contractions push the food forward against a closed sphincter,
the pylorus, until the particles are small enough (2–5mm) to pass
through to the duodenum. In the duodenum, the particles are mixed
with bile which is produced by the liver and stored in the gall bladder
between the meals, and the alkaline pancreatic digestive juices con-
taining lipase and proteases.
After the stomach, for eﬃcient digestion by other enzymes, the pH
must be raised and transit patterns be appropriate to the complete di-
gestion of the meal during a single transit period. Some of the end
products of digestion are relatively polar: amino-acids, mono-
saccharides etc. and must be absorbed by active transport. They are
valuable, so this will be achieved against an unfavourable
concentration gradient by expending energy. The length of the small
bowel, consisting of the proximal jejunum and distal ileum, varies be-
tween 3 and 8m (Teitelbaum et al., 2013), and provides a large surface
area for absorption of nutrients, liquid and medicinal products.
Undigested products reach the colon through the ileocaecal valve.
In the colon, bacterial fermentation of the undigested ﬁbres will take
place. After absorption of the excess liquid, the stools will be retained in
the left hemicolon and the rectum until defecation upon relaxation of
the internal and external anal sphincters.
This is the scenario for oral medication: eﬀectively deliberately
consuming a poison which for the most part must be absorbed into the
systemic circulation. If the material is not recognised, then it must be
small enough to be absorbed passively through transcellular and/or
paracellular routes. If it is designed to mimic an essential component in
the diet or part of the drug motif looks like a nutrient, then it may be
handled by active transport and show saturability as part of the ab-
sorption process. Because drugs are partially ionised as weak bases or
acids and will partition, regional absorption will occur where contact is
suﬃcient for the drug in solution to be absorbed into membrane and
where the pH yields suﬃcient material in a non-ionised form to be
taken up into the enterocyte and then onwards to the systemic circu-
lation and other organs.
The European Network on Understanding Gastrointestinal
Absorption-related Processes (UNGAP) aims to improve our under-
standing of intestinal drug absorption by creating a multidisciplinary
network of researchers from academia and industry engaging in sci-
entiﬁc discussions. This review will summarize the current knowledge
on anatomy and physiology of the human gastrointestinal tract with
emphasis on human studies for the evaluation of the regional drug
absorption and the prediction of oral dosage form performance.
2. The gastrointestinal mucosa
2.1. Regional mucosal diﬀerences
The gastrointestinal mucosa is the innermost structure of the di-
gestive tract that inﬂuences digestion, absorption and secretion. Being
in direct contact with the luminal content, the epithelial monolayer of
the mucosa is important in regulating the passage of nutrients, ions, and
solutes through paracellular and transcellular pathways. The epithelial
cells are supported by a basement membrane composed of extracellular
matrix components including laminins, collagens and proteoglycans,
and act together as a barrier between the luminal content and the im-
mune system. The underlying loose connective tissue is the lamina
propria, which provides support and nutrition to the epithelium (Van
Eyken et al., 2014). The functional diﬀerentiation of the GI mucosa
diﬀers both between and within the tissue of the stomach, small in-
testine and large intestine, leading to region dependent properties af-
fecting drug absorption (Fig. 2).
The stomach has two functional regions: the oxyntic gland area
(fundus and corpus) and the pyloric gland area (antrum). The oxyntic or
acid secreting area of the stomach aids in chemical digestion, and is
characterized by vertical tubular indentations consisting of an apical pit
region, an isthmus and a gland (Schubert and Peura, 2008). The pro-
genitor cells are located in the isthmus and can diﬀerentiate into all the
gastric cell types while migrating, and establish an epithelial layer that
is regenerated every 2–4 days (Creamer et al., 1961). Stem cells can
diﬀerentiate into surface mucous cells while migrating upwards, and
HCl-secreting parietal cells, pepsinogen secreting chief cells and en-
teroendocrine cells which migrate downwards (Schubert and Peura,
2008). The surface mucous cells secrete an adherent mucus layer that
has a mean thickness of 180 μm, range: 50–450 μm (Jordan et al., 1998)
(Newton et al., 2000) (Newton et al., 1998) (Kerss et al., 1982) (Al-
Marhoon et al., 2005), which hydrates to form two distinct layers on the
intestinal epithelium, protecting the stomach from self-digestion (Van
Den Abeele et al. 2017a). Mucus is a hydrocolloid composed of water
Fig. 1. The human gastrointestinal tract.
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(95%), lipids, electrolytes, and glycoproteins. The secretion of gel-
forming mucins occurs in a region dependent manner along the GI tract
(Kim and Ho, 2010; Teubl et al., 2013), with up to 20 diﬀerent mucins.
Gastric mucus is predominantly enriched with the gel-forming protein
MUC5AC (Johansson et al., 2011), nevertheless mucins present in ad-
jacent crypts can be diﬀerently glycosylated (Andrianifahanana et al.,
2006; Kim and Ho, 2010). Interspersed between parietal cells are
neuroendocrine, enterochromaﬃn-like cells (EC cells) which aid in the
secretion of acid by release of histamine (Soybel, 2005). These re-
present 30–50% of enteroendocrine cells in the oxyntic mucosa (Zhao
and Chen, 2012; Chu and Schubert, 2013). Enteroendocrine cells are
the largest endocrine organ (< 1% of gut epithelial cells) of the human
body (Chen et al., 1999; Schubert and Peura, 2008), and regulate se-
cretion, motility, food intake and metabolism. A (and GR cells), G and D
cells can be found in the stomach as well and secrete ghrelin, gastrin
and somatostatin respectively. G and D cells are also present in the
small intestine (Latorre et al., 2016).
Intestinal cells originate from multipotent LGR5+ stem cells in the
base of glandular crypts (Loeﬄer et al., 1993; Barker et al., 2007) and
have a high cellular turnover rate (Creamer et al., 1961). Stem cells of
the small intestine give rise to a monolayer of enterocytes that is
characterized by protrusions that extend into the gut lumen, called villi,
resulting in a potential absorptive surface area of 60m2 in both the
jejunum and ileum. In this way, the small intestine maximizes ab-
sorption of nutrients, in addition to aiding in chemical digestion. Villi
are surrounded by epithelial invaginations termed the crypts of
Lieberkühn (where stem cells reside in the base) (Clevers, 2013), in
contrast to the colon where the surface area totals around 0.25m2 as
there are no villi (Kararli and Searle, 1995). The amount of goblet cells
increases along the gastrointestinal tract, ranging from 4% in the
duodenum to 16% in the distal colon (Cheng, 1974; Kim and Ho, 2010).
The MUC2- rich mucus is a thin and discontinuous layer (Szentkuti and
Lorenz, 1995; Bajka et al., 2015) in the small intestine that facilitates
the absorption of a larger range of molecular nutrients, opposed to the
thick two layer system in the colon (range: 20–52.5 μm) (Strugala et al.,
2008). The colonic mucus consists of a stratiﬁed and sterile inner mucus
layer, which can be reformed by endogenous proteases into a thicker
and more porous outer (loose) mucus layer to allow a symbiotic re-
lationship with microbiota (Johansson et al., 2011; Sellers and Morton,
2014). The loose mucus can be degraded by bacteria, thereby facil-
itating the passage of ingesta (Birchenough et al., 2015). An intact
colonic mucus appears to be completely clear from bacteria in a zone of
about 30 μm which does not stain. The underlying mucosa remains
immunologically quiescent (Swidsinski et al., 2007). Johansson and
colleagues have also identiﬁed the two-layer structure of colonic mucus
with an inner zone devoid of bacteria and an upper zone that is colo-
nised by bacteria and varies in thickness as mucin is digested
(Johansson et al., 2008). The mucus of the small intestine and caecum
however is enriched with antimicrobial peptides from Paneth cells
(Ayabe et al., 2000; Van Eyken et al., 2014), thereby protecting it not
only from physical and chemical stress, but also exerting a bactericidal
eﬀect. EC cells in the small intestine can either be ‘open cells’, where
Fig. 2. The functional diﬀerentiation of the gastrointestinal mucosa.
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the microvilli are in direct contact with the gut lumen, or ‘closed cells’
that are indirectly regulated through neural and humoral mechanisms
(Sternini et al., 2008). Apart from D and G cells in the small intestine,
this area is also typiﬁed by I and K cells that secrete cholecystokinin and
gastric inhibitory polypeptide respectively, while both the small intes-
tine and colon produce 5-HT. L cells are located in the distal small in-
testine and colon, with GLP-1, GLP-2, PYY and 5-HT identiﬁed as the
main products (Latorre et al., 2016).
2.2. Region dependent drug absorption
Oral drug absorption is region dependent and is inﬂuenced by the
mucus layer, intercellular tight junctions, and the expression of trans-
porters and enzymes in epithelial cells.
It has been postulated that electrostatic interactions and the pore
size of the mucin network can aﬀect the mobility of particles, especially
molecules with a higher molecular weight including peptides and DNA
(Kirch et al., 2012; Bajka et al., 2015). Firstly, mucus can limit the
absorption rate and bioavailability due to the chemical interactions
between glycoproteins and the drug. Hydrophilic drugs generally
permeate freely through the mucus layer, but permeation can be hin-
dered at a pH > 2.6 due to electrostatic interactions between the ne-
gatively charged mucins and the positively charged drugs. Drugs can
also show aﬃnity for the hydrophobic protein core of mucins or for
hydrogen bonding (Varum et al., 2012). Secondly, gel-forming mucins
can have size ﬁltering properties. The mucus mesh size of human sali-
vary mucin ﬁbres was determined as around 0.8 μm (Teubl et al., 2013)
which was similar to the pore size of porcine mucin in the stomach. It
was noted that nanoparticles cannot always reach the membrane of the
epithelial cells, as they get captured in the glycocalyx. However, by
developing mucoadhesive systems that surpass the mucus turnover, the
epithelium can still absorb the drugs released from the nanoparticles
(Huckaby and Lai, 2018). In addition, PEGylated nanoparticles have
been shown to diﬀuse rapidly in physiological mucus, approaching si-
milar ﬂuxes through water (Lai et al., 2007). The thickness and com-
position of mucus diﬀers regionally, which suggests a slowed-down
diﬀusion and a lower permeability through the mucus, but also implies
that it is region dependent (Falavigna et al., 2018).
The passive paracellular absorption of drugs is dependent on the
expression and regulation of tight junctions, which are found in the
most apical part of the junction complexes that connect neighbouring
epithelial cells. Tight junctions are expressed diﬀerentially between
stomach, small bowel, and large bowel (Rahner et al., 2001; Hewitt
et al., 2006; Lu et al., 2010; Lu et al., 2013). This results in a barrier that
is relatively leaky in small intestinal tissue, while gastric and colonic
mucosa are of intermediate tightness. The diﬀerential expression of
claudins between regions is the main determinant of these barrier
properties, with claudin-1, -3, -4, -7, and -8 being expressed most pre-
valently in the colon, and claudin-2, -7, -8, and -9 in the upper intestinal
tract. Claudins can be selective for cations (claudin-2, -10b, -15), or
anions (claudin-10a, -17), water (claudin-2) or not selective at all
(claudin-4, -8, -14) (Krug et al., 2014). Sjöberg and colleagues showed
that highly permeable lipophilic drugs tend to have the same or higher
permeability coeﬃcients in the colon in comparison with the small
intestine, while the reverse is true for more polar compounds (Sjoberg
et al., 2013; Peters et al., 2016).
Eﬄux pumps at the (apical) membrane can play pivotal roles in the
transcellular absorption, distribution and excretion of drugs by facil-
itating the excretion of xenobiotics and endogenous compounds. In the
intestine, ATP-binding cassette (ABC) transporters are among the most
highly expressed transporters (colon: P-gP (5%), BCRP (3%), MRP2
(25%), small intestine: PgP (8%) BCRP (4%), MRP2 (10%)) (Drozdzik
et al., 2014) and together they function as a signiﬁcant barrier to in-
testinal absorption, especially as they have a partially overlapping
substrate spectrum (Misaka et al., 2013). The abundance of P-gP in-
creases from the proximal to the distal region of the small intestine,
while the opposite is true for CYP3A4 (Drozdzik et al., 2014; Li et al.,
2016). Due to the synergistic interplay of CYP3A and P-gP on dual
substrates and the long intestinal transit time, compounds can undergo
extensive presystemic intestinal metabolism (Siissalo and Heikkinen,
2012; Peters et al., 2016). However, so far site-dependency has only
been conﬁrmed for substrates of PgP. Furthermore, region dependent
uptake can be attributed to diﬀerences in intracellular metabolism, with
higher rates of intracellular metabolism leading to sink conditions in-
side the cells (Peters et al., 2016).
3. The unstirred water layer
The unstirred water layer (UWL) exists above the epithelium as a
stagnant boundary layer of varying dimensions. It is a general phe-
nomenon of wetted objects, even on non-biological surfaces (Green and
Otori, 1970) and for the gut forms part of the barrier for molecules
diﬀusing across from the luminal space into the cell. The relative con-
tribution of the unstirred water layer in measurements of drug ﬂux is
known to vary in diﬀerent in vitro preparations and in clinical trials
under diﬀerent conditions, especially as a function of mixing and be-
cause motility changes occur along the gut, it contributes to measure-
ments of regional drug absorption in the gut.
In early physiological experiments, amphibian preparations were
widely used by physiologists as frogs were readily available and cold-
blooded so easy to use in a laboratory environment. The dimensions of
the UWL on frog skin were determined by Dainty and House (1966),
using potassium sulphate or sodium sulphate as a probe. The mea-
surement indicated a layer within the dimensions of 120–230 μm for
potassium ions dependent on stirring conditions but the analysis ig-
nored the contribution of ﬁxed surface charges. Sodium sulphate gave a
value of around 30–50 μM, suggesting that the resistance to transport of
the sodium ion was much nearer to the surface. Similar values and
diﬀerences were calculated under moderate stirring conditions by
others for the same tissue (Kidder et al., 1964). Dainty and House also
noted that the resistance to sodium movement occurs within the
membrane, as had been noted by Winn's group (Dainty and House,
1966; Winn et al., 1964). Winn reported that when an epidermis be-
comes vacuolated under osmotic drive, the sodium diﬀusion coeﬃcient
increased ten-fold. This suggested to Dainty and House, that a pre-
dominant barrier to solute diﬀusion might also lie in the cytoplasm
(Dainty and House, 1966). Thus, there would be inner and outer UWL
resistance as discussed later by Westergaard and Dietschy (1974).
In well culture systems, the apparent UWL measurements above the
planar surface of the well can extend to 1200–1500 μm. Transport rates
are routinely normalised to the surface area of the conﬂuent monolayer
and since even vigorous shaking in a well culture system leaves a UWL
thickness of between 500 and 1000 μm, the true Michaelis constant of
an enzymatic process, Kt, may be elusive. For example, Shibayama and
colleagues report that the common methods of estimating the kinetics
of the organic cation transporters OCT and MATE1 by Chinese hamster
ovary cells yields overestimates the true Kt by two to ten-fold
(Shibayama et al., 2015). Hidalgo and colleagues have described in-
creasing mixing by gas lift to calculate the mixing forces needed to
decrease the UWL in trans-well cell culture. As the UWL was reduced
from 1966 to 564 μm, an increase in the diﬀusion rate constant of
testosterone from 3.08× 10–5 cm·s−1 under stagnant conditions to
14.08×10–5 cm·s−1 at a ﬂow rate of 40mL·min−1 (Hidalgo et al.,
1991) was noted.
If a UWL overlays a tissue with geographic tortuosity, that it is to
say it is highly folded at microscopic dimensions or is within an un-
stirred matrix as would be found in spaces between and under cells, the
eﬀects of water stagnancy become more evident. Conversely, if the
surface layer is subjected to shear on a relatively ﬂat surface, such as a
ﬂat mounted rat jejunum, the UWL thins dramatically (Thomson and
Dietschy, 1980).
In the gut, Winne showed that the uptake rates of butanol,
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antipyrine, salicylic acid and urea were increased in a perfused rat je-
junal loop. This was attributed to alteration of the UWL and to in-
creased surface area for absorption (Winne, 1978). Winne calculated
that the UWL contributed between 10 and 36% of transport resistance.
Small molecules shuttle in the intracellular space (active transport be-
tween cells) or are transiently displaced during an action potential.
These processes may be coupled to water ﬂow - for example overall ﬂux
is assisted by the sodium-glucose linked cotransporter, SGLT1 which is
a highly eﬃcient engine for passive water movement across the intes-
tine (Erokhova et al., 2016).
3.1. Measurements of UWL
The UWL in the gut has been described as two regions: that on the
apical surface and that between villi (Westergaard and Dietschy, 1974).
With stirring, the apical layer in a ﬂat surface mounted rabbit jejunum
shear thins. The change in UWL is calculated by measuring the t1/2 in
transmucosal potential diﬀerence change following the exposure to a
hyperosmotic solution. The time to achieve the new steady state is a
function of the UWL thickness and diﬀusivity of the probe molecule
(Diamond, 1966). Barlow and colleagues have recently described a
rheological device based on measurement of a droplet interface bilayer
(Barlow et al., 2017). Di Cagno and colleagues have measured the
diﬀusivity by time-resolved UV measurements quantifying the move-
ment of a concentrated solution at the base of the well of a cuvette and
monitoring changes in absorbance over a 24-hour period (di Cagno
et al., 2018).
Calculation of the UWL of gut segments in vivo often assumes a
measurement based on a smooth cylinder surface area. The gut is highly
folded and has villus projections contributing to kVF, the surface ex-
pansion factor. This is a measure that calculates the contribution of the
folds of Kerckring to the expansion of the luminal surface area, com-
pared to a simple tube. In a recent paper by Lozoya-Agullo and col-
leagues, the ﬁgure cited is a kVF of 4.6. This would indicate that the
UWL calculated by one of her co-authors Dr. Marival Berjemo of 103 μm
(Bermejo et al., 2004) for a closed perfused rat loop (known as a Do-
lusio preparation), would be 2506 μm (Lozoya-Agullo et al., 2018). In
man, the more folded intestine results in a kVF of value of 33 versus a
kVF of 2.9 to 3.1 in rats, due to higher density of villi and the presence
of plaecal folds in the human intestine which are not present in rat
(DeSesso and Jacobson, 2001). Read and colleagues attempted to
measure the thickness of the unstirred water layer and electrogenic
glucose absorption using a multi-lumen tube by sequentially infusing
solutions containing sodium chloride, mannitol and glucose (Read
et al., 1977). Measurements were made on healthy controls and patients
with coeliac disease who had active status or who had been treated. The
data indicated a mean thickness in healthy adults of 632 ± 24 μm,
decreasing to 442 ± 23 μm in patients with active disease. The thick-
ness of the UWL in treated coeliac patients was nearer to healthy con-
trols (585 ± 49 μm). Levitt and colleagues calculated the unstirred
water layer from measurements of the hydrolysis of the disaccharides,
sucrose and maltose. The measurements suggested that the unstirred
diﬀusion layer of the human jejunum was only around 35 μm. Although
a UWL of 600 μm as estimated from electrogenic measurements would
be rate limiting, epithelial cell function and lumenal stirring would be
more likely barriers if the UWL were so thin (Levitt et al., 1992). Static
systems are to a large extent unrepresentative of events likely to be
encountered in vivo. In any case, in seemingly poorly stirred systems,
stochastic events occur. Barry & Diamond observed that even on ﬂat
surfaces, water layers will be subject to convective ﬂow due to solute
gradients, small temperature gradients and water density gradients
(Barry and Diamond, 1984). The authors suggest that when active and
passive transport of a solute is balanced, the concentration in the UWL
will be the same as in the bulk phase; however, if the solute is trans-
ported out of the cell the UWL concentration increases. The con-
sequence for eﬄux transport from the Barry & Diamond perspective is
that the concentration-driven gradient for the solute would be de-
creased. Changing the architecture of the mucosal membrane by
stretching causes shortening and swaying movements of the villi (Lee,
1983) although larger movements of the intestine are more eﬀective in
changing the absorptive surface. Smaller canine jejunal biopsy samples,
which were stretched showed increased water absorption suggesting
changes in the sub-villous architecture facilitates water removal by the
lymphatic system. Increasing villus motility by mechanical agitation
was also investigated in sections from along the canine gut by Mailman
and colleagues, who reported that this was without eﬀect on the UWL
(Mailman et al., 1990). An increase in perfusion rates in the partially
obstructed rat ileal preparation from 1 to 100mL/min increases the
absorption of glucose by 150% which was attributed to increased mu-
cosal surface area (Lewis, 1975). Conversely, a distension of the intes-
tine was found to increase the inter-villus width, without an eﬀect on
total surface area (Scott-Harris et al., 1988).
3.2. Agitation, UWL and the movement of molecules
The absorption of BCS class II drugs is limited by transport of the
dissolved species through the UWL since permeation through the
membrane is rapid for highly lipophilic drug such as danazol (Kataoka
et al., 2012). Incorporating the drug in a system that facilitates mole-
cular dispersion or promotes low interactivity e.g. shields long range
interactions caused by ionization, reduces the interactions within the
UWL and increases the rate of permeation. The link between permea-
tion and solubility driving the thermodynamic activity of a drug, clas-
sically determines the proportional rate of transport of a drug (Higuchi,
1977). Later researchers have commented that the ﬂux can be alter-
natively considered as the interplay between solubility and perme-
ability ignoring thermodynamic arguments (Dahan et al., 2016; Beig
et al., 2017a). As an example, generating a large solubilised species
such as a micelle will impact inherent diﬀusivity rates and reduce the
free concentration in the unstirred water layer. In some situations, the
inﬂuence of the membrane eﬄux pump will dominate and be highly
non-linear and any inﬂuence of the UWL will not be apparent. This is
true for the BCS class IV molecule rifamixin, a rifampicin analogue.
Dahan and colleagues described the inﬂuence of a supersaturated ri-
famixin formulation on rat intestinal absorption of the drug. At 1× and
100× supersaturation, ﬂuxes were similar whereas at 250× super-
saturation absorption rose; however, this eﬀect was not apparent in an
artiﬁcial PAMPA membrane (Dahan et al., 2016), since both solubility
and permeability were increased by the amorphous solid dispersion
(Beig et al., 2017b).
Within the dissolving formulation, a temporary association of drug
with excipients and natural gut secretions will form complex structures
that would be slow to diﬀuse across the UWL and therefore it is un-
surprising that agitation in Caco-2 systems increases the movement of
very large constructs. Kono and colleagues demonstrated that the UWL
in culture was a signiﬁcant barrier to the eﬃciency of transfection with
a liposomal /pDNA complex (Kono et al., 2016).
3.3. The role of mucus in the UWL
The surface mucins extend 200 to 1500 nm above the epithelium
anchored to the glycocalyx, an integral part of the plasma membrane.
The external surface expresses glycoproteins and glycolipids, attached
to adherent mucins to form the ﬁrmly adherent mucin layer (30 μm).
The mucins hydrate, swell and become more loosely adherent becoming
sheared by peristalsis (Atuma et al., 2001; Kim and Ho, 2010). Where
shear forces are lower and there is a higher density of goblet cells, i.e. in
the colon, the thickness increases markedly up to 1.5 mm. Thus, a
principle eﬀect of mucin secretion is to increase the thickness of the
UWL.
The thickness of the UWL within the mucus will vary as muscular
movements through the colon are sluggish. Although scientists are very
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familiar with the protective role of the mucus in the colon, they may
have ignored the small intestine. Here intestinal mucus may also have
an important role to protect the villus against insult (Bryan et al., 1980)
and secretion is increased by goblet cell capping: the process by which
the apical concentration of goblet cells increases. There is no doubt that
an attached mucoid layer will support the UWL in the same manner as
other large hydrophilic polymers as described in the experiments of
Jenkins and colleagues and those of Johnson and Gee (Jenkins et al.,
1978; Johnson and Gee, 1981, 1982).
The eﬀects of artiﬁcially supplementing the barrier properties of the
UWL have been considered by nutritionists, particularly in the treat-
ment of obesity. Possible clinical advantages of dietary ﬁbre in the
management of oral glucose loads for diabetic patients were ﬁrst re-
ported by Jenkins and colleagues. They compared various ﬁbres and
drew attention to the role of guar gum and pectin in mediated post-
prandial glycaemia (Jenkins et al., 1978). The eﬀect of viscous poly-
mers on absorption of sugars was further explored by scientists at the
Agriculture Research Centre in Norwich, a group that did much re-
search on the beneﬁts of ﬁbres in diet though the 80's. Using everted gut
sacs, it was shown that enhanced viscosity reduced stirring in the in-
tervillous compartment slowing presentation to the membrane surface
enzymes. It was also hypothesized that the increased UWL thickness
produced a partial anoxia (oxygen starvation) in the preparation, re-
ducing the generation of ATP to drive active transport (Johnson and
Gee, 1982). Blackburn and Johnson examined the eﬀects of guar gum,
diluted in saline and found that the system markedly increased the
UWL, resulting in a resistance to absorption (Blackburn and Johnson,
1983). Smithson and colleagues attempted to separate the barrier
properties of the UWL from the mucus layer component and concluded
that the UWL had a lesser role than the secreted mucus as large mo-
lecules, including the probe [125I]-labelled lactoperoxidase, could not
get access to the membrane of the intact enterocyte layer due to the
presence of the mucus coat (Smithson et al., 1981).
Secretions produced near a wall will aid mixing since the chyme is a
weak gel which forms a matrix when static. When secretions are wa-
tery, shear induced by muscular motion of the intestinal wall produces
ﬂow; conversely, if ﬂuid content is a stronger gel or contains more
particulates, the mass in the lumen will show elastic distortion and
reestablishment (Lentle and De Loubens, 2015). The authors also
comment that the individual movement of villi do not contribute to
mixing but rather it is the villus crowding that occurs as peristaltic
movements of circular and longitudinal muscle causing a distortion of
the lumen.
3.4. The UWL acid microclimate
It has long been established that the surface layer on top of the
mucosa is acidic even when bulk buﬀer pH is near to neutrality as
shown in everted gut sacs with a 60 μm electrode (Lucas et al., 1975).
Lucas also reported the acid microclimate in vivo, using anaesthetized
rats with an exteriorized jejunal loop bathed with Krebs-Heinsleit bi-
carbonate buﬀer at pH of around 7.2. The pH in the UWL as the probe
microelectrode was advanced to the surface using a micromanipulator
and was shown to approach a pH around 5.9 (Lucas, 1983). The surface
pH became alkaline in the ileal segment, becoming slightly more al-
kaline than the perfusing buﬀer. During anoxia, in the presence of
glucose, the jejunal tissue microclimate remained acidic whereas in the
absence of glucose, the acid microclimate drifted back to normal. It
appears that during periods of anoxia, the gut uses apical transporter
pumps protonated metabolites (such as lactate) into intestinal lumen.
Note that Caco2 monolayers are unable to support this acid micro-
climate which has to be mimicked in culture to obtain more re-
presentative behaviour (Gleeson et al., 2017).
4. The intraluminal environment
4.1. Physicochemical characteristics and intraluminal composition
In oral drug absorption studies, the fasted state is typically deﬁned
as the period immediately after the ingestion of a glass of water and
until the consumption of the next meal, provided that the water is
consumed approximately 12 h, after the last meal (Food and Drug
Administration, 2002; European Medicines Agency, 2010). The fed
state, on the other hand, is typically deﬁned as the period from 30min
after the start of consumption of a high-fat, high-calorie
(800–1000 kcal) meal until the stomach is practically emptied from
meal components, provided the meal is consumed 12 h, after the last
one (Food and Drug Administration, 2002; European Medicines
Agency, 2010).
4.1.1. Stomach
The stomach is the ﬁrst organ in which intense and prolonged
contact between an orally ingested formulation and any gastrointestinal
ﬂuids takes place. Inevitably, this environment will aﬀect local for-
mulation and drug behavior. Gastric ﬂuids consist of a variety of
components that are either secreted by the stomach (e.g. gastric acid,
enzymes, electrolytes, mucus), swallowed/ingested (e.g. saliva, food,
liquids) or reﬂuxed from the duodenum in the stomach (e.g. bile con-
stituents). In this regard, the stomach is a somewhat special case as the
physicochemical characteristics of its contents are directly aﬀected by
anything ingested. Hereafter, the physicochemical characteristics of the
gastrointestinal environment are discussed in the fasted state, after
ingestion of a glass of water and in the fed state. In general, ingestion of
water can be viewed as a temporary dilution of gastric contents.
Ingestion of a meal will initially result in a gastric ﬂuid composition
that closely resembles that of the meal. During digestion and gastric
emptying of that meal the gastric environment will gradually change
back to baseline (fasted) conditions. The composition of these stomach
ﬂuids will aﬀect formulation disintegration and drug dissolution and/or
solubility. Moreover, the high variance of these contents will install
variability local and systemic drug disposition.
In general, the gastric environment is reported as typically acidic
due to the secretion of hydrochloric acid by parietal cells lining the
gastric wall. Median gastric pH values between 1.5 and 1.9 have been
measured (Pedersen et al., 2000; Pedersen et al., 2013; Lindahl et al.,
1997; Press et al., 1998; Dressman et al., 1990). However, a wide range
of pH values was observed (1.4 to 7.5). In the fundus, the lower density
of parietal cells gives rise to a pH shift to between 2.2. and 4. Low pH
values will be recoded if the probe penetrates mucus as the contribution
of surface bicarbonate is reduced. High pH values measured in gastric
samples likely result from swallowing saliva and/or sporadic duode-
nogastric reﬂux. After water ingestion, pH values may vary between 1.6
and 3.3 although initial gastric pH exhibited large inter-individual
diﬀerences with values ranging from pH 1–8 (Kalantzi et al., 2006;
Koziolek et al., 2014a; Petrakis et al., 2015). In the postprandial state,
the ingested meal volume and composition will be the main determi-
nants of initial postprandial pH (Koziolek et al., 2013; Kalantzi et al.,
2006; Dressman et al., 1990) The timeframe for re-acidiﬁcation will
depend on the buﬀer capacity of the administered meal as well as the
rate at which the meal is emptied from the stomach (Kalantzi et al.,
2006; Dressman et al., 1990; Simonian et al., 2005). Dressman and
colleagues for example reported a timeframe of< 2 h to reach pH 2 in
the postprandial stomach after ingestion of a solid meal (1000 kcal)
(Dressman et al., 1990).
The average buﬀer capacity of gastric contents in the fasted state
have been reported as 14.3 ± 9.5mmol·L−1·ΔpH−1 (N=19)
(Pedersen et al., 2013). Water intake will dilute gastric content, re-
sulting in a temporary decrease in buﬀer capacity (Kalantzi et al., 2006;
Litou et al., 2016). Following a meal, the buﬀer capacity of gastric
content is expected to initially be similar to that of the ingested meal.
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Kalantzi et al. for example observed buﬀer capacity's ranging from 14 to
28mmol·L−1·ΔpH−1 following the ingestion of a liquid meal. These
values are close to the buﬀer capacity of the meal itself (i.e.,
mmol·L−1·ΔpH−1) (Kalantzi et al., 2006).
Viscosity measurements in human gastric aspirates are character-
ized by large variability within and between studies. The viscosity of
fasted gastric aspirates has been reported in ranges from 1.7 to
9.3 mPa·s (shear rate= 50 s−1, N=17). Gastric aspirates are observed
to be inhomogeneous resulting in marked intra-sample variability
(Pedersen et al., 2013). Upon meal intake, gastric viscosity initially
increases, depending on meal composition, and subsequently declines
due to dilution of gastric content resulting from stimulated gastric se-
cretion (Abrahamsson et al., 2005; Marciani et al., 2000; Radwan et al.,
2014).
Gastric ﬂuids contain important amounts of enzymes, which are
mainly involved in the digestion of meal components. Two of the main
digestive enzymes present in the stomach are pepsin and gastric lipase.
Pepsin is secreted as the inactive pepsinogen, which is converted to
pepsin in the presence of luminal gastric acid (pH < 5) (Soybel, 2005;
Gritti et al., 2000; O'Connor and O'Moráin, 2014). The activity of pepsin
has been reported to be maximal at pH 2 and non-existent at pH 5.5 or
higher (Johnston et al., 2007). Furthermore, pepsinogen output has
been observed to signiﬁcantly increase after ingestion of a meal
(Kalantzi et al., 2006). In a similar way, gastric lipase is only active
within a speciﬁc pH range with a maximal activity reported between
pH 3–5.5. As enzymatic activity is most likely either very low or non-
existent in fasted state, mainly data on gastric lipase activity in fed
human subjects have previously been reported in literature (Pedersen
et al., 2013; Ville et al., 2002; Williams et al., 2012). Interestingly,
reports indicated a considerably more extensive digestion of
triglycerides in the stomach after intake of a liquid meal compared to
solid meals, due to a better pre-emulsiﬁcation of dietary lipids in a li-
quid meal (Carrière et al., 2001; Renou et al., 2001; Carrière et al.,
2005; Borgstrom et al., 1957; Carrière et al., 2000; Bergström et al.,
2014).
Surface tension is mainly inﬂuenced by the presence of pepsin and
the sporadic reﬂux of duodenal content in the stomach (Pedersen et al.,
2013; Efentakis and Dressman, 1998; Bergström et al., 2014). In fasted
volunteers, values of 34.8 ± 5.2mN·m−1 (N= 19) and 35 to
45mN·m−1 (N=8) are reported (Pedersen et al., 2013; Efentakis and
Dressman, 1998). Slightly higher surface tension is observed in gastric
ﬂuid from volunteers ingesting water (Kalantzi et al., 2006). Further-
more, Kalantzi et al. observed surface tensions 30% lower after intake
of a liquid meal (Kalantzi et al., 2006).
The presence of proteins (e.g., pepsin) and electrolytes determines
the osmolality of gastric content. Without prior water intake, mean
osmolality (± SD) of human gastric aspirates has been reported to be
191 ± 36mOsm·kg−1 (N=36) and 220 ± 58mOsm·kg−1 (N=19)
(Lindahl et al., 1997; Pedersen et al., 2013). Several authors have ob-
served a considerable decrease in osmolality of gastric aspirates im-
mediately after water intake. For instance, 10min after water admin-
istration, Petrakis et al. measured an osmotic value of 32mOsm·kg−1 in
pooled gastric aspirates (Petrakis et al., 2015). After meal ingestion, the
properties of the meal will dictate osmolality of gastric ﬂuids in fed
subjects. For instance, 30min after intake of a liquid meal, osmolality of
gastric content was found to be similar to that of the meal as such (559
vs. 610mOsm·kg−1, respectively) and to decrease to fasted state values
within 3.5 h as the meal is emptied from the stomach (Kalantzi et al.,
2006).
Fig. 3. pH (a and b) and buﬀer capacity (c and d) data collected immediately upon aspiration of samples from the upper intestine at various times after adminis-
tration of a glass of water to fasted adults (fasted state, a and c) and a homogenous or heterogenous liquid meal to fasted adults (fed state, b and d). Only studies
which did not involve co-administration of an ionizable drug were considered.
Fasted state: empty boxplot (Litou et al., 2016); lined boxplot (Kalantzi et al., 2006); solid squares (Riethorst et al., 2016; mean values); open triangles (Clarysse et al.,
2009; median values).
Fed state: empty boxplot (Vertzoni et al., 2012 - heterogeneous liquid meal); lined boxplots (Kalantzi et al., 2006 - homogeneous liquid meal); solid squares (Riethorst
et al., 2016 - homogeneous liquid meal; mean values); Open triangles (Clarysse et al., 2009 - homogeneous liquid meal; median values).
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4.1.2. Upper intestine (duodenum and proximal jejunum)
Unlike in the fasted state, to date, the physicochemical character-
istics and composition of contents of upper intestine in the fed state
have been investigated only to a limited extent, partly due to diﬃculties
in sampling from the region. Data have been collected, after adminis-
tration of liquid meals having caloric content and origin of calories
similar with those in meals which are typically administered in oral
drug absorption studies (Pentafragka et al. 2019). Information from
studies which did not involve co-administration of agents which could
potentially aﬀect the luminal environment (e.g. ionizable drugs) is
summarized below.
The average pH is slightly acidic in the fasted state with median
values from various studies ranging between 6.1 and 7.0. However, at
least during the ﬁrst hour after administration of a glass of water
variability is high and pH values as low as 3 can occur (Fig. 3a). In the
fed state, data collected after administration of homogenous or het-
erogenous liquid meals indicate slightly decreased pH values during the
course of digestion with the medians ranging between 4.8 and 6.5
during the ﬁrst 3 h post meal administration (Fig. 3b). It is interesting to
note that during the ﬁrst hour post meal administration data variability
is lower than during the ﬁrst hour after administration of a glass of
water (Fig. 3a vs. b).
Median values ranging from 5.7 to 11.5 mmol/L/ΔpH have been
reported for the buﬀer capacity of contents in upper intestine im-
mediately upon aspiration of samples in the fasted state (Fig. 3c).
Corresponding values in the fed state are on average more than double,
and, apparently, only slightly aﬀected by the course of digestion
(Fig. 3d). It should be noted that buﬀer capacity measurements should
be performed immediately upon aspiration of samples, because of the
instability of the bicarbonate-CO2 buﬀer (the main buﬀering species in
the fasted state) and the potential continuation of digestion of meal
components in the fed state during handling and storage of the aspi-
rated samples.
Although variable in total, sodium and chloride concentrations are
almost equivalent, about 100mM on average, both in the fasted and in
the fed state (e.g. Pentafragka et al. 2019). Potassium concentrations
are about 10 times lower and calcium concentrations are minimal with
the potential impact of food intake on luminal concentrations of these
two cations, unclear. Duodenal contents are hypo-osmotic in the fasted
state (median range: 115–206mOsm/kg) but they are mostly hyper-
osmotic in the fed state; median values at various times during the ﬁrst
3 h after meal administration range from 215mOsm/kg (at 3 h) to
423mOsm/kg (at 2 h). Duodenal surface tension seems to be slightly
higher in the fasted state; reported median values range from 32.7 mN/
m to 35.3mN/m in the fasted state and from 30.2 mN/m (at 3 h) to
35.1 mN/m (at 0.5 h) in the fed state. Total bile salt content is variable
but, on average, it is higher in the fed state; median values from various
studies in the fasted state range from 3.7mM to 7.7mM whereas overall
median values during the ﬁrst 3 h, after the administration of a liquid
meal, range from 3.7 mM (at 3 h) to 18.2mM (at 1 h). A median value
of 11.5 has been reported for the ratio [total bile salt content/phos-
pholipids] in the fasted state and a value of about 3.4 for the fed state.
Cholesterol levels and variability increase after meal intake; median
values in the fasted state range from 0.08mM to 0.44mM whereas
median values at various times up to 3 h after meal administration
range from 0.30mM (at 3 h) to 3.12mM (at 1 h). Glyceride, free fatty
acid and carbohydrate content should be considered with caution as
relevant concentrations are minimal in the fasted state and exclusively
dependent on the speciﬁc meal composition in the fed state. Informa-
tion on total protein content has been collected using kits and should
also be considered with caution. The protein content in the fasted upper
intestine reﬂects primarily the presence of pancreatic enzymes. A 5- to
10-fold increase in pancreatic lipase and a 5-fold increase in phospho-
lipase-A2 are observed in the fed state (Riethorst et al., 2016). Since
food intake reduces the mean ﬂuid volumes in the small intestine
(Schiller et al., 2005) and pH values are only slightly aﬀected,
substantially higher enzyme activity is expected in the upper intestine
in the fed state.
4.1.3. Lower intestine (distal ileum and proximal colon)
The emphasis to date has been on the physicochemical character-
ization of the environment in healthy adult upper GI tract as the oral
drug absorption is usually complete in the upper small intestine.
However, diﬀerences in the luminal environment between the upper
small intestine and the lower intestine (distal ileum and proximal
colon) may impact the performance of orally administered products
which deliver drug during residence in the lower intestine. More spe-
ciﬁcally, in cases where an extended release or a colon targeting pro-
duct is administered or where the drug has low permeability in the
upper intestine but can be absorbed to some extent during its residence
in the lower intestine, the environment in the lower intestinal lumen
will inﬂuence drug/drug product performance (Diakidou et al., 2009).
Over the last decade, a well-deﬁned protocol for direct sampling
from the lower intestine with minimal eﬀects on its physiology has been
proposed and this provided a basis for the physicochemical character-
ization of contents collected from the lower intestine under conditions
to which drugs/drug products are exposed during BA/BE studies in
healthy adults (Diakidou et al., 2009; Reppas et al., 2015). Samples
have been collected, ﬁve hours after the administration of a glass of
water or after the consumption of the high-fat, high-calorie meal {as
proposed by regulatory agencies (Food and Drug Administration, 2002;
European Medicines Agency, 2010)] i.e. when drugs administered as
conventional products or multiparticulate modiﬁed release products are
expected to reach the lower intestine after oral administration.
In the distal ileum, the pH is slightly alkaline (median pH 8.1) re-
gardless the dosing conditions. In the proximal colon (cecum and as-
cending colon) the pH in the fasted state is about 7.8 whereas in the fed
state it is lower, about 6.0 (Fig. 4A), due to the increased bacterial
fermentation activity after the consumption of the meal [Koziolek et al.,
2015]. As with pH, buﬀer capacity does not diﬀer between prandial
states in distal ileum but it diﬀered in the proximal colon. Compared to
caecal and ascending colon contents, ileal contents have signiﬁcantly
lower buﬀer capacity only in the fed state (Fig. 4B). It is interesting to
note that buﬀer capacity of ileal contents is similar with values reported
for duodenal and jejunal contents in the fasted state (Diakidou et al.,
2009; Reppas et al., 2015). In line with the lower pH values and the
higher buﬀer capacity of caecal contents compared to ileal contents,
total short chain fatty acid (SCFA) concentration is higher in cecum
than in distal ileum in both prandial states. Although the presence of
SCFAs did not diﬀer between prandial states in these two regions, a
signiﬁcant food eﬀect was observed in the contents of ascending colon
(Fig. 4C).
Osmolality of ileal contents in the fasted state is lower than in the
fed state [mean (SD) 60(50) vs 252(245) mOsmol/Kg) but osmolality of
caecal and ascending colon contents do not diﬀer between prandial
states (Fig. 4D) (Diakidou et al., 2009, Reppas et al., 2015). Lower in-
testinal contents are generally hypoosmotic with values lower than in
the duodenum in both prandial states (Pentafragka et al., 2019).
Protein content is lower in the fed state samples but total carbo-
hydrate concentrations are higher (Fig. 4E and F). This can be explained
by the fact that digestion and absorption of peptides administered with
the meal is almost complete by the end of the ﬁrst meter of the small
intestine but carbohydrates administered with the meal may or may not
be digested in the small intestine and may therefore reach the colon
(Pentafragka et al., 2019). It has been reported that total carbohydrate
content in the fed colon was approximately 30% of that observed in the
fed upper small intestine (Kalantzi et al., 2006, Diakidou et al., 2009,
Reppas et al., 2015).
In the ileal and caecal contents, diﬀerences in bile salt concentra-
tions between the prandial states are not marked but in the contents of
the ascending colon bile salt concentrations are higher in the fed than in
the fasted state (Diakidou et al., 2009, Reppas et al., 2015). In all cases,
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due to bile acid reabsorption in the distal ileum, bile acid concentra-
tions in the lower intestine are signiﬁcantly lower (mean values range
from 70 to 500 μM) than in the upper small intestine, regardless of the
prandial state (Pentafragka et al., 2019). Higher concentrations of pri-
mary bile acids (cholic acid, chenodeoxycholic acid) than secondary
bile acids (deoxycholic acid, lithocholic acid) have been observed in the
fed ascending colon, which is the opposite to the fasted state situation.
Diakidou and colleagues concluded that that as more bile acids enter
the colon after the consumption of a meal, the capacity for conversion
to secondary bile acids is saturated, resulting in more bile acids in the
primary form (Diakidou et al., 2009).
Caecal and ascending colon contents have almost twice the con-
centration of free fatty acids concentration than ileal contents in both
prandial states. Concentration of total phospholipids (phosphati-
dylcholine and lyso-phosphatidylcholine) in distal ileum did not diﬀer
signiﬁcantly in the fasted state compared to the fed state. In the fasted
state, total concentration of phospholipids is increased signiﬁcantly
from distal ileum to cecum and then to the ascending colon. In the fed
state, there is no diﬀerence in phospholipids between distal ileum and
cecum but there is an increase in the ascending colon. Cholesterol levels
do not diﬀer within each region of the lower intestine with the dosing
conditions (Diakidou et al., 2009; Reppas et al., 2015; Pentafragka
et al., 2019).
4.2. Availability and distribution of ﬂuids in the human GI tract
In terms of oral drug delivery, luminal ﬂuids have two major
functions. Firstly, they are needed to dissolve the drug as it is widely
accepted that only drug in solution can be absorbed. Secondly, luminal
ﬂuids enable drug absorption by bringing the dissolved drug into con-
tact with the absorptive tissues of the GI tract and by acting as a carrier
during the uptake into systemic circulation. Hence, the knowledge of
Fig. 4. pH, buﬀer capacity, short chain fatty acids concentration, osmolality, protein content and carbohydrate content of the contents of distal ileum (plain light-
yellow boxes), of cecum (lined light-yellow boxes) and of ascending colon (plain dark green boxes) of healthy volunteers measured in the fasted and in the fed state. n
is the number of subjects contributed to the construction of box plots. For each box plot and from bottom to top continuous horizontal lines indicate the 10th, 25th,
50th (median), 75th and 90th percentile, black dots indicate the individual outlying data points, and dotted line indicates the mean value.
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the availability and distribution of luminal ﬂuids is a prerequisite for
successful oral drug delivery. However, it must be kept in mind that the
ﬂuid volumes in all parts of the GI tract are highly dynamic and the
result of an interplay between secretion, absorption as well as ante-
grade and retrograde transfer of contents. In general, the human GI
tract handles 8–10 L of ﬂuids each day. From this volume, only about
2–3 L arise from the intake of food (20–30%) and drinks (70–80%). The
major part is due to the secretion of digestive juices. Most of this water
is absorbed in the upper intestine, but each day around 1.5 L of ﬂuid
arrive in the colon. Only about 200mL of water are excreted via the
feces (Jéquier and Constant, 2010; Ritz and Berrut, 2005). This daily
ﬂuid turn-over in the human GI tract certainly aﬀects drug absorption
and therefore, the availability and distribution of ﬂuids within stomach,
small intestine and colon as well as their implications for oral drug
absorption shall be described in the following sections. Particular at-
tention will be paid to the dynamic changes of ﬂuid volumes in the
diﬀerent parts of the GI tract.
4.2.1. Stomach
The storage of incoming food as well as its enzymatical, chemical
and physical processing are the main functions of the stomach.
Simultaneously, it delivers small portions of pre-digested contents, the
so-called chyme, to the small intestine, where nutrient and drug ab-
sorption can take place. Thus, the volume of gastric contents is the
result of the volume of incoming food and liquids, the volume of oral
and gastric secretions minus the volume of contents emptied into the
small intestine. To the best of our knowledge, absorption of water from
the stomach can be neglected.
In the fasting state, the residual ﬂuid volume is generally small with
values below 100mL as was shown in various MRI studies (Grimm
et al., 2018a; Mudie et al., 2014). In a recent publication by Grimm and
colleagues the interindividual range of residual volumes in the stomach
aver an overnight fast of at least 10 h was 17–93mL with a mean of
49 ± 19mL. The intraindividual range was comparable and amounted
to 22–77mL with a mean 44 ± 18mL (Grimm et al., 2018a).
The ﬂuid dynamics after intake of food and liquids depends mainly
on the caloric value of the ingested contents. Whereas non-caloric ﬂuids
are emptied rapidly, the gastric emptying of caloric contents can take
up to several hours, depending on further parameters such as food
texture or caloric density. From a regulatory point of view, the intake of
a drug on a fasted stomach is deﬁned as the intake of the drug together
with 240mL water after a fasting period of minimum 8 h. The resulting
gastric ﬂuid volumes over time were studied recently by Mudie and
colleagues with the aid of magnetic resonance imaging (MRI). It can be
seen from Fig. 5 that the initial ﬂuid volume measured 2min after ﬂuid
intake reaches a level of 242 ± 9mL. Since this volume is already
lower than the sum of the ingested water and the residual gastric ﬂuid,
which would be 275mL, it can be assumed that gastric emptying of
non-caloric ﬂuids starts almost immediately. Subsequently, gastric
emptying follows 1st order kinetics and after around 30–45min the
gastric ﬂuid volume typically returns to levels measured prior to water
intake (Mudie et al., 2014).
On the other hand, the intake of food can cause elevated gastric
content volumes (GCV) for several hours, which can have dramatic
consequences for the gastric residence times of oral drug products as
well as drug release from these products. It was recently shown that
after the ingestion of the high-caloric (800–1000 kcal), high-fat stan-
dard breakfast, as recommended by FDA and EMA for studies, in which
the food eﬀect on oral bioavailability or bioequivalence in the fed state
is tested, the GCV rises from 4 to 65mL in fasted state to 500–628mL
directly after meal intake (Fig. 6) (Koziolek et al., 2014a, 2014b). This
volume is the sum of the volumes of the meal, residual gastric contents
as well as oral (e.g. saliva) and gastric secretions. The contribution of
digestive juices to ﬂuid volume in the stomach should not be under-
estimated. Whereas unstimulated salivary ﬂow rates are in the range of
0.1–0.5 mL/min, stimulated salivary ﬂow can be up to 10mL/min. As
the majority of this volume is swallowed, oral secretions account for a
considerable part of the total gastric volume. Gastric secretions are also
stimulated by meal intake in order to allow suﬃcient digestion of the
food. In the fasted state, gastric secretion rates of 1mL/min or lower are
described in literature (Dubois et al., 1977), whereas after consumption
of solid foods initial gastric secretion rates of 10mL/min and higher can
be measured (Malagelada et al., 1976). In an MRI study published by
Sauter and colleagues, approximately 50% of the gastric content vo-
lume present 100min after intake of 400mL of a viscous chocolate
Fig. 5. Mean gastric volume ± SEM before and after the intake of 240mL of
water at t=0min in 12 healthy subjects. Reprinted from Mudie et al., 2014,
with permission from the ACS. Further permissions related to the material ex-
cerpted should be directed to the ACS.
Fig. 6. Individual gastric content volumes (mL) over time (min) determined
before and after administration of the high-caloric FDA breakfast in 12 healthy
volunteers by using MRI. The gastric content volume at 0min represents the
residual gastric content volume after an overnight fast of at least 10 h. All
subjects consumed the entire meal within 15min. After 30min, the subjects
drank 240mL of water inside the MRI scanner in order to simulate the intake of
water during drug administration. Adapted from Koziolek et al. (Koziolek et al.,
2014a, 2014b).
M. Vertzoni, et al. (XURSHDQ-RXUQDORI3KDUPDFHXWLFDO6FLHQFHV²

drink was due to gastric secretions (Sauter et al., 2011). It can be seen
from Fig. 6 that the GCV is fairly constant for the ﬁrst 60–90min, which
may be explained by the circumstance that secretion and emptying are
in balance. Interestingly, during this time the intake of 240mL of water
(after 30min) only causes a minor peak in GCV that disappears quickly
within 15–35min. This distinctive proﬁle is the result of the Magen-
strasse (stomach road), a mechanism that allows the fast emptying of
liquids from the fed stomach (Koziolek et al., 2014a, 2014b). In a
follow-up study, the presence of the Magenstrasse was also conﬁrmed
for other foods that diﬀered in texture and caloric density (Grimm et al.,
2017). With respect to oral drug delivery, this mechanism is highly
relevant as it allows the early emptying of drug into the small intestine
and thus, the early onset of systemic drug concentrations, given disin-
tegration of the dosage form and drug dissolution are fast as well. Re-
cently, Sager and colleagues have developed a simple and reliable
technique to describe gastric emptying of water in both fasted and fed
state. This method is based on the quantiﬁcation of caﬀeine in human
saliva and can be easily combined with conventional pharmacokinetic
studies (Sager et al., 2018). By this, the contribution of gastric emptying
to the onset of systemic drug concentrations can be evaluated.
In contrast to the emptying of liquids, the gastric emptying of solid
foods can be typically described by zero order kinetics. As a rule of
thumb, the gastric emptying rate of caloric contents typically amounts
to 2–4 kcal/min. In case of the FDA standard breakfast, the GCV de-
creases with a relatively constant rate of 1.7 ± 0.3 mL/min. Thus,
even>6 h after meal intake the GCV is still elevated compared to the
GCV measured prior to meal intake. However, by this time the meal will
be highly diluted owing to ongoing secretion and emptying. In any case,
it should be noted that mixing in the stomach is not as vigorous as
generally assumed. Marciani and co-workers nicely illustrated by MRI
that dilution of a viscous locust bean gum meal with gastric secretions is
slow (Marciani et al., 2001). Unfortunately, little is known about the
ﬂuid dynamics in the human stomach since the in vivo imaging of these
processes is complex. Nonetheless, in silico simulations based on com-
putational ﬂuid dynamics by Ferrua and Singh suggest that peristaltic
waves cause higher shear rates in the antrum, which facilitates mixing
of gastric contents with secretions (Ferrua et al., 2014; Ferrua and
Singh, 2010). In contrast, in the fundus mixing is generally poor. Thus,
a dosage form located in the fundus will be exposed to small shear
stresses and low shear rates, whereas in the antrum, shear rates and
stresses are higher. This may have dramatic consequences for disin-
tegration of dosage forms as well as the process of dissolution. Longer
localization within the fundus can be expected to be responsible for the
lag times often seen after drug administration in the fed state (Koziolek
et al., 2016).
4.2.2. Upper intestine
As mentioned earlier, the availability of ﬂuids within the small in-
testine is a prerequisite for drug absorption as ﬂuids play a major role in
dissolution, distribution of the drug within the intestinal lumen and
absorption. In particular, for poorly water-soluble drugs administered
at higher doses the dissolution of the drug in intestinal ﬂuids may be
problematic. On the other hand, dissolution in small volumes may lead
to high concentrations thereby facilitating processes including passive
diﬀusion and/or saturating eﬄux transporters.
The availability and distribution of ﬂuids within the small intestine
was largely unknown, but novel imaging techniques such as magnetic
resonance imaging were successfully applied in in the recent ﬁfteen
years to shed light on this important aspect of oral drug delivery.
Schiller and co-workers were among the ﬁrst to apply MRI in order to
measure the ﬂuid volumes in the small intestine in fasted and fed state
(Schiller et al., 2005). They demonstrated that the small intestinal ﬂuid
volume in the fasted state can be highly variable and ranging from 45 to
319mL. On average, the small intestinal ﬂuid volume was measured as
105 ± 72mL. However, this volume is distributed over the entire
length of the small intestine in several “ﬂuid pockets”. The largest ﬂuid
volume is typically present in the terminal ileum, because contents
accumulate at the ileocaecal junction before they are transferred into
the caecum. One hour after the intake of a high-caloric breakfast, the
ﬂuid volume amounted to just 54 ± 41mL, which was signiﬁcantly
lower than the fasted state volume. Again, the distribution of ﬂuid in
various “ﬂuid pockets” was observed. In a later study, the changes of
intestinal ﬂuid volumes were investigated over a period of> 8 h by
Marciani and co-workers. They also found a decreased ﬂuid volume
after 1 h, but on further study, they revealed that the ﬂuid volume
begins to increase after around 90min and a maximum ﬂuid volume is
reached after approximately 3 h. At this time, the volume is slightly
higher compared to fasted state values (Marciani et al., 2010).
Several MRI studies have also looked at the contribution of certain
nutrients on small intestinal ﬂuid volumes. Grimm and colleagues have
shown that small intestinal ﬂuid volume after intake of grapefruit juice
is elevated for longer times compared to the intake of the same volume
of water. Whereas initially the small intestinal ﬂuid volumes are com-
parable, the ﬂuid volume 80min after drinking was twice as high as for
the grapefruit juice compared to water (Grimm et al., 2018b). The
authors assumed that this can alter drug absorption of certain drugs.
The diﬀerent volumes can be explained by the presence of fructose,
which is absorbed slowly and thus causes water inﬂux into the in-
testinal lumen due to osmotic eﬀects (Murray et al., 2014).
Groups have also tried to determine the rate of water absorption
from the small intestine by using D2O as a marker. Péronnet and col-
leagues obtained a rate of 3–3.5 mL/min for intestinal water absorption
after intake of 300mL of water by pharmacokinetic modeling (Péronnet
et al., 2012). However, other groups determined rates of up to 25mL/
min with signiﬁcant regional diﬀerences. Lambert and colleagues de-
monstrated that water absorption in the proximal intestine is higher
compared to distal parts (Lambert et al., 1997). The net water ﬂux
across the intestinal membrane is further aﬀected by secretion of ﬂuids
and is thus aﬀected by the osmolality and the electrolyte and nutrient
(e.g. carbohydrates) composition of the intestinal contents (Shi and
Passe, 2010).
In general, it should be considered that the ﬂuid turn-over is highly
dynamic. Secretion, absorption as well as transport of ﬂuids in ante-
grade and retrograde directions all occur at the same time.
Unfortunately, the kinetics of these processes are still largely unknown
and therefore, it is almost impossible to assess the role of ﬂuid in oral
drug delivery. We have noted in past MRI studies that ﬂuid present in
the small intestine can disappear almost instantaneously from the
lumen, but re-appear in another moment. Whilst ﬂuid ﬂow across the
mucosa is not fully understood and more or less unpredictable, phar-
maceutical scientists should be careful in using intestinal ﬂuid volumes
for in vitro and in silico simulations.
4.2.3. Lower intestine
Roughly 1–2 L of intestinal contents are transferred into the large
intestine every day, from which around 200mL are excreted via the
feces each day. During colonic transit, the viscosity of the contents
increases, whereas the volume of free ﬂuid decreases. Hence, the con-
ditions for drug dissolution in the colon are relatively poor, which
should be particularly concern in the development of colon-targeted
dosage forms.
The MRI study by Schiller and colleagues revealed that the luminal
ﬂuid volume in the colon in fasted state is relatively small with mea-
sured values in the range of 1–44mL and a mean of 13 ± 12mL. This
ﬂuid is found primarily in several ﬂuid pockets located in the ascending
and descending colon. After meal intake, the colonic ﬂuid volume
slightly increases to values of 2–97mL with a mean of 11 ± 26mL.
The number of ﬂuid pockets was also higher in the fed state (Schiller
et al., 2005). In a later study, Murray and co-workers investigated the
ﬂuid volume in the colon and the number of ﬂuid pockets in fasted state
(Murray et al., 2017). After an overnight fast of at least 10 h, the sub-
jects drank 240mL of water. Subsequently, the volumes of free ﬂuid
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were measured over a time course of 2 h. Fig. 7 illustrates that the li-
quid volume reached its maximum 30min after ﬂuid intake, and again
shows the large variability of colonic ﬂuid volumes. Moreover, free li-
quid was found to be mainly present in the ascending colon. The data
presented in this work are useful for the characterization of the con-
ditions in bioequivalence and bioavailability studies: The observed in-
crease in colonic ﬂuids probably resulted from the gastroileal reﬂex,
and it is unlikely to be the ﬂuid that was recently ingested.
In an aspiration study, Reppas and colleagues were able to collect
5.0 ± 2.1mL from the fasted caecum and 8.0 ± 2.7mL from the fed
caecum (Reppas et al., 2015). In an earlier study, the same group col-
lected contents from the ascending colon with the aid of a colonoscopy
over a period of approximately 10min (Diakidou et al., 2009). In this
study, the volume of the contents in the ascending colon was
22.3 ± 7.7mL in the fasted state and 29.9 ± 10.8mL in the fed state.
Interestingly, the aqueous fraction was higher in fasted state
(70.3 ± 17.0%) as compared to the fed state (56.0 ± 9.0%). These
values correlate well with the MRI data described above.
It should be noted that the availability of ﬂuids for dissolution and
absorption also depends on colonic motility, since it aﬀects dosage form
transit through the colon as well as the transit of luminal contents. Only
dosage forms that are in contact with ﬂuid are able to release the drug
in a relevant manner. However, drug absorption is typically limited to
proximal parts of the colon (Wilson, 2010).
The review to this point has considered ﬂuids and an understanding
of some of the microstructural components of the gut wall. Fluid, food
and drug forms are propelled by mechanical forces in the gut. In the
clinic, the applications of imaging have been especially important in the
diagnosis of disordered of gastrointestinal transit. These technologies
have been adopted in pharmaceutical sciences to examine regional
transit-absorption relationships.
5. Human studies to evaluate regional drug absorption
5.1. Imaging
Modern imaging techniques oﬀer some options to study the fate of
orally administered drugs and the inﬂuence of regional diﬀerences in GI
tract. Mostly, the position of a drug delivery system in the GI tract can
be more reliably determined using imaging techniques than with other
methodologies like for example electronic delivery capsules equipped
with pH sensors, since even strong pH changes are not necessarily
correlated with gastrointestinal transport events (Koziolek et al., 2014a,
2015; Schneider et al., 2016).
The diﬀerent imaging methods have several distinct areas of ap-
plication, as for example the tracking of dosage forms, the determina-
tion of dosage form, disintegration and dissolution, as well as the
evaluation of luminal ﬂuid volumes and their transfer. Furthermore,
imaging techniques are utilized as an aid for correct gastrointestinal
placing of intraluminal tubes. In these cases, Fluoroscopy is usually
applied in order to verify the correct placement of catheters in the GI
tract (Van Den Abeele et al., 2016; Yu et al., 2017). Moreover, the
tracking of electronic capsules with programmable release (see Section
5.3.1.) via imaging techniques has also been used to verify their loca-
lization for site speciﬁc release, absorption or sampling purposes (Clear
et al., 2001; Martin et al., 2003).
The in vivo visualization of molecules in humans is established for
the investigation of the distribution and elimination of labelled drug
substances such as 18F-ﬂuorouracil (Saleem et al., 2000), or 212Pb-
TCMC-trastuzumab (Meredith et al., 2014). However, the spatial and
temporal resolution as well as the detection sensitivity of common
imaging techniques is not high enough to visualize directly the trans-
port of (even labelled) molecules through the intestinal wall. In addi-
tion, regulatory issues with such labelled drug substances often hinder
human application. Therefore, for the evaluation of site-speciﬁc drug
release or absorption, a combination of the simultaneous determination
of drug absorption via pharmacokinetic measures and imaging of the
location of the usually labelled drug or drug delivery system is applied.
Thus, one main utilization of imaging techniques is the evaluation of
transit conditions and site-speciﬁc release of dosage forms. Un-
fortunately, only a few sets of imaging data with focus on site speciﬁc
absorption are available, although it well known that dosage form
transit can massively inﬂuence subsequent absorption and exposure as
shown for several drugs (Varum et al., 2010).
It should be appreciated that the gastric fate of a dosage form and
the region-speciﬁc circumstances in the stomach are likely to cause
diﬀerences in subsequent absorption. In that regard, gastric emptying
and transit has extensively been studied using several imaging techni-
ques in the fasted and the fed states, as detailed in Section 4.2 (Jones
et al., 2012; Koziolek et al., 2014b; Mudie et al., 2014; Weitschies and
Wilson, 2011). From imaging studies, there is no evidence for relevant
drug absorption in the human stomach as gastric emptying correlates
Fig. 7. Individual (A) as well as mean ± SEM (B) colonic liquid volumes over time as determined by MRI in 12 healthy subjects. At t=0min all volunteers drank
240mL of water on a fasted stomach. Reprinted from Murray et al., 2017 (https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.7b00095), with permission from
the ACS. Further permissions related to the material excerpted should be directed to the ACS.
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extremely well even in case of highly absorbable drugs like caﬀeine and
paracetamol (Paulick and Siegmund, 2013; Sager et al., 2018). Thus,
drug absorption in humans is predominant in the small intestine or
sometimes also the colon whilst gastric emptying often determines the
absorption rate (Koziolek et al., 2016; Van Den Abeele et al., 2017a).
5.1.1. Results from human studies
The site speciﬁc disintegration and release of dosage forms can be
studied in humans with several techniques including scintigraphy,
magnetic resonance imaging (MRI), magnetic marker monitoring
(MMM), alternating current biosusceptometry (ACB), radiography or
ﬂuoroscopy (Hunter and Taljanovic, 2003; Klausner et al., 2003;
Sjögren et al., 2014; Weitschies and Wilson, 2011; Wilding et al., 2001).
The most commonly reported approach to evaluate site speciﬁc ab-
sorption with imaging techniques is the combination of scintigraphy
and pharmacokinetics, also referred as pharmacoscintigraphy
(Srivastava et al., 2014). It requires the inclusion of a gamma-emitting
radiopharmaceutical in the delivery system. The suitable tracer can be
incorporated during the formulation of the dosage form, which is often
a challenge with respect to the half-lives of the radioisotopes, or sub-
sequently via a “drill and ﬁll” procedure which is also common for
labeling with ferromagnetic material as required for MMM. In this case
a hole is drilled into the already produced dosage form (typically a
tablet), the labeling material is included and the hole is sealed with a
suitable substance afterwards. Sometimes the label can also be attached
to the surface of a dosage form. This is most useful for oesophageal
transit studies since the disturbed surface is not in contact with the
mucosa.
A special approach is the combination of scintigraphic tracking of a
programmable or remote-controlled telemetric device such as the
InteliSite® capsule and pharmacokinetics. In this case, a marker sub-
stance of choice for scintigraphic detection can be included into the
drug reservoir. Several insights have been obtained using this approach.
For example, a study using an investigational capsule which releases
furosemide and theophylline on ﬁring release in the gut showed a poor
absorption of furosemide and theophylline from the colon, and also a
much slower release and distribution due to the highly viscous colonic
contents (Clear et al., 2001). It was also shown that leuprolide acetate is
nearly not absorbed from the ileum and the colon (Doll et al., 1997) and
that ranitidine is absorbed from the jejunum and the ileum to the same
extent and rate (Pithavala et al., 1998). Using a radiolabeled electronic
delivery capsule, it was observed that lumiracoxib is well absorbable
from the proximal and the distal small bowel as well as from the colon
(Wilding et al., 2004). The evaluation of tacrolimus also showed ab-
sorption from small intestine and colon (Tsunashima et al., 2014). In all
of these studies, GI transit was evaluated in real time by gamma scin-
tigraphy and release was triggered by remote control. Studies with la-
belled dosage forms have been performed to study regional drug ab-
sorption. Extended release morphine tablets with diﬀering release
characteristics were investigated and absorption of morphine was ob-
served throughout the entire GI tract, although the release was reduced
in distal parts (Olsson et al., 1995).
The investigation of diltiazem dosed as extended release pellets or
as a solution in fasted and fed state showed that diltiazem was rapidly
absorbed in the upper GI tract from the solution whilst diltiazem ab-
sorption from the pellet formulations continued for> 12 h, irrespective
of fasted or fed state. No relevant diﬀerences in the PK proﬁles were
observed, although the pellets had already arrived the colon after fasted
administration at these late time points. Thus it seems that diltiazem
can be absorbed from the colon to the same extent like from the small
bowel and altered media did not aﬀect the PK (Wilding et al., 1991).
This was also observed with modiﬁed release mini tablets containing
diltiazem (Wilding et al., 1995).
For other drug substances a high impact of gastrointestinal transit
has been observed, for example in case of saquinavir administered as
capsules in the fed or fasted state. In this case it could be demonstrated
that saquinavir is best absorbed from the upper small intestines, since
emptying of intact capsules from the stomach after intake under fasting
conditions resulted in a passage of unreleased substance through the
regions with high absorption capacity and thus a reduced bioavail-
ability. In contrast, the slow gastric emptying of dispersed saquinavir
after capsule disintegration in fed stomach led to a higher absorption in
the upper small intestinal region (Kenyon et al., 1998).
The concept of insuﬃcient contact time to regions where absorption
takes place is well established and has been addressed in the transit
parameters including MTT (mean transit time), MRT (mean residence
time), and MAT (mean absorption time) (Darwich et al., 2016). This
was nicely demonstrated for geﬁtinib. Subjects with faster gastro-
intestinal transit showed a reduced bioavailability which was attributed
to slow absorption from the upper GI tract and insuﬃcient absorption
in more distal regions (Wilson et al., 2009).
Colon targeting of locally acting substances like mesalazine (5-ASA)
is another ﬁeld for the application of imaging methods. For example, for
diﬀerent time controlled formulations of mesalazine aimed for colon
targeting, it could be demonstrated that mesalazine absorption corre-
lated with time and site of disintegration (Steed et al., 1997). In a study
with 4-aminosalicylic acid (4-ASA) it could be shown that only the
metabolite was found in plasma if the disintegration took place in colon
(Tuleu et al., 2002).
In case of ziprasidone, low colonic absorption has been observed
(Thombre et al., 2015). In contrast, scintigraphic studies with modiﬁed
release formulations of tamsulosin, dexamethasone or ibuprofen
showed good absorption from colon for these drugs (Hodges et al.,
2013; Kenyon et al., 1997; Wilson et al., 1989).
In addition to the scintigraphic investigations, it became also fea-
sible to use MRI to study gastrointestinal transit, at least for single unit
dosage forms. For example, ferromagnetic iron oxides can be used to
visualize the location but probably not the disintegration of dosage
form. Therefore, a combination with an absorbable marker substance or
the drug substance of interest was required. Although there are several
studies concerning the tracking of dosage form (Chaddock et al., 2014;
Hahn et al., 2011; Kagan et al., 2006; Steingoetter et al., 2003), this
method was typically not used for evaluation of site speciﬁc absorption
but rather site speciﬁc disintegration (Grimm et al., 2019).
5.1.2. Pitfalls
Although imaging is usually performed to verify the localization in
the GI tract, this issue may not optimally addressed with most of the
applied imaging techniques so far described. In common gamma scin-
tigraphy, a radiopharmaceutical is detected in 2-dimensional imaging
therefore, the exact localization in GI tract could be doubtful in some
investigations since the regional location lacks the anatomical refer-
ences. This may lead to a some complications regarding estimation of
the position of the dosage form in the GI tract, since gastrointestinal
anatomy diﬀers even between healthy subjects (Srivastava et al., 2014).
Comparable problems account for MMM and other techniques which
also require anatomical location.
When using scintigraphy, this can be partially overcome by labelling
of co-administered water with [99mTc]-DTPA chelate (Wilson et al.,
2009) or of food labelled with 99mTc sulphur colloid which roughly
delineates anatomical contours of the GI lumen(Cole et al., 2004). In
addition, a commonly used approach is to use thoracic front and back
“anatomical locators” by the attachment of one or more closed point
sources with the radionuclide being measured aﬃxed to the subject.
Subsequent analysis uses acetate maps to locate gastric and colonic
positions revealed by dispersion or second label to these landmarks
(remembering to physically mark the skin!). Since a considerable in-
terindividual variability in anatomical orientation and morphology has
been reported by several workgroups, this might not be suﬃcient for a
very speciﬁc and narrow deﬁnition of location in the GI tract (Sandberg
et al., 2015; Steingoetter, 2015).
These problems can be avoided using MRI as it provides excellent
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anatomical images allowing the detection of the interindividual varia-
bility in GI anatomy as illustrated in Fig. 8.
5.2. Intraluminal sampling
Although the inﬂuence of GI physiology on intestinal drug disposi-
tion is extensive, the underlying mechanisms often remain diﬃcult to
identify. Indirect methods including deconvolution and PBPK modeling
do not always capture the level of complexity involving a physico-
chemical event interacting in a variable physiological environment. To
assist in understanding drug and formulation behaviour, direct mea-
surement of intraluminal drug concentrations through local sampling
allows integration of all the cogent data. Independent of regional dif-
ferences, GI absorption is driven by local drug concentrations.
Intraluminal sampling enables the determination of drug
concentrations at the site of interest (stomach or intestine). When
performing gastric and intestinal drug disposition studies, one (Fig. 9A)
or more catheters (Fig. 9B) are introduced through the mouth or nose of
a human volunteer. Catheters are positioned under ﬂuoroscopic gui-
dance and can be led through the pylorus to reach the small intestine
(Brouwers et al., 2007). A schematic overview is provided in Fig. 9.
Following correct positioning, volunteers can ingest a drug formulation,
sometimes in combination with a solid or liquid meal (Brouwers et al.,
2007). Gastric and intestinal ﬂuids can subsequently be retrieved as a
function of time, resulting in a detailed GI drug concentration proﬁle
(Brouwers et al., 2005). Following aspiration, these ﬂuids can also be
analyzed for physicochemical properties, enzyme activity and/or bile
salts (Brouwers et al., 2007; Walravens et al., 2011; Riethorst et al.,
2016). It should be noted that studies using catheters placed inside the
GI tract are inherently invasive in nature and can thus potentially aﬀect
Fig. 8. Variability of intestinal anatomy within three subjects in T1w MRI.
Fig. 9. Schematic overview of intraluminal sampling tech-
nique. Left: Catheter(s) are introduced through nose (A) and
mouth (B) and positioned inside the stomach and the in-
testine. Right: X-ray images of (A) one catheter positioned
inside the stomach and the intestine (A) and (B) a catheter
positioned inside the stomach (solid line) and a catheter
positioned inside the intestine (dotted line); catheters are
traced for clarity.
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normal gastrointestinal physiology. However, several studies indicate
minor or non-signiﬁcant eﬀects of transpyloric tubes on gastric emp-
tying, gastric secretions and duodenogastric reﬂux (Go et al., 1970;
Longstreth et al., 1975; Näslund et al., 2000; Read et al., 1983; Rees
et al., 1979).
Intraluminal sampling is often combined with concomitant blood
sampling to relate gastrointestinal drug and formulation behavior to
systemic drug disposition (Brouwers et al., 2007). In this case, as in-
traluminal sampling inevitably includes removing a certain amount of
drug from the intraluminal environment, the volume of aspirated
sample should be limited.
5.2.1. Gastric drug disposition studies
Various small-scale (typically 5 to 10 volunteers) clinical studies
have been reported in which gastric drug disposition has been linked to
systemic concentrations. For instance, Brouwers and colleagues mon-
itored GI concentrations of fosamprenavir after oral ingestion of a
commercial formulation (Telzir®). A food-induced delay in systemic
amprenavir absorption was correlated to the postponed dissolution of
the fosamprenavir tablet in the stomach as observed in the gastric
concentration-time proﬁle (Brouwers et al., 2007). Walravens and
colleagues investigated the eﬀect of pH and co-medication on the gas-
trointestinal absorption of posaconazole. Posaconazole was adminis-
tered as a suspension to healthy volunteers with water or a cola bev-
erage, with or without prior proton pump inhibitor administration.
Although co-administration with a cola beverage did not alter the pH of
the intraluminal environment compared to administration with water,
it did increase posaconazole gastric concentrations which related to an
increase in systemic exposure. Co-administration of esomeprazole led to
an increased gastric pH, which was accompanied by decreased gastric
and systemic exposure. Using intraluminal sampling, this study in-
dicated that dissolution of posaconazole in the stomach dictates its
systemic absorption (Walravens et al., 2011).
Gastric sampling studies can be expanded with simultaneous mea-
surements of GI motility. Intraluminal pressure waves can be monitored
in real-time using high resolution manometry (HRM). This technique
uses a catheter with multiple pressure sensors along its length. Van Den
Abeele et al. used this combined collection techniques to study the ef-
fect of sparkling water on the gastric behaviour of a paracetamol for-
mulation (Dafalgan®) (Van Den Abeele et al., 2017b). In this study,
volunteers were asked to ingest a paracetamol tablet with either tap
water or sparkling water, after which gastric drug concentrations and
gastric motility including other factors were monitored. When the for-
mulation was ingested with sparkling water, faster drug absorption was
observed which could be linked to faster intragastric tablet disin-
tegration combined with increased gastric motility. A typical con-
centration drug proﬁle of one volunteer from this study is given in
Fig. 10. This investigation illustrates the potential intraluminal sam-
pling can provide in capturing the interaction between GI physiology
and in vivo drug disposition.
5.2.2. Intestinal drug disposition studies
Besides gastric drug disposition, several studies have been published
in which intestinal drug disposition was linked to systemic pharmaco-
kinetics (Van Den Abeele et al., 2017c; Hens et al., 2016b; Hens et al.,
2016a; Hens et al., 2015; Koenigsknecht et al., 2017). Van Den Abeele
and colleagues monitored intestinal and systemic drug concentrations
in healthy volunteers after oral intake of a commercial tablet of diclo-
fenac (Cataﬂam®). A good correlation was found between the time
needed to achieve maximal systemic drug concentrations (tmax) and
maximal dissolved drug concentration in the duodenum (Fig. 11a) (Van
Den Abeele et al., 2017c). Fig. 11b depicts the systemic concentration-
time proﬁle of a healthy volunteer.
5.2.3. In vivo permeability assessment
A more advanced application of intraluminal sampling is the Loci-I-
Gut® Perfusion method. This method uses a multi-lumen catheter whose
design includes two latex balloons that can be inﬂated to isolate a
certain intestinal segment. This segment is subsequently perfused with
a drug solution and the permeability is determined from the dis-
appearance of drug during perfusion (Knutson et al., 1989). This
method can also be applied to determine intestinal drug metabolism
and luminal excretions (Petri et al., 2003) (Tannergren et al., 2003).
In the next section, the information on gastrointestinal transit
gathered from indirect tests is considered. Such tests, which include
breath tests, impedance monitoring of the stomach and ultra-
sonography will yield less information compared to more establishes
digital imaging techniques but have special attributes for certain pa-
tient and volunteer groups.
5.3. Indirect sampling
5.3.1. Breath tests
In many gastrointestinal diseases, an alteration of gastrointestinal
transit signals neuromuscular dysfunction, obstruction or an in-
ﬂammatory condition and measurement of the pathophysiological
changes useful in assisting interpretation and treatment. Early diag-
nostic studies of gut behaviour were conﬁned to x-ray contrast tests
using opaque markers or whole gut transit measurements using co-
loured beads (Wilson, 2010). Gamma scintigraphy of labelled meal
components provided more representative regional gut transit in-
formation and therefore was more valuable. Scintigraphy is a gold
standard for assessing changes in gastrointestinal transit as good ana-
tomical resolution is not essential; however, it does expose the patient
to low doses of radiation which is of concern where the very young or
pregnant females are investigated. For several reasons therefore, a
simpler technology may be useful provided that it has robust end
points. In the case of the breath test, the concept was to use the
Fig. 10. Drug concentration determined in gastric ﬂuids aspirated as a function of time from one healthy volunteer after intake of 1 tablet of Dafalgan® (500mg
paracetamol) with either 330mL of tap water (left) or 330mL of sparkling water (right). Inserts depict the pH of gastric aspirates as a function of time. Data adopted
from Van Den Abeele et al. (2017b).
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bacterial fermentation of a carbohydrate to release hydrogen that
would be exhaled.
The concept of using breath tests in metabolic studies had been
stimulated by early studies of breath alcohol measurement described
and used as the basis of patented instruments through 60's and 70's
(Borkenstein and Smith, 1961; Borkenstein, 1971). Gas chromato-
graphy was then a new analytical instrument, essential in the oil and
gas industry, which was beginning to be used for medical applications.
Later applications have included detection of volatile components in-
cluding alkanes in the breath of patients with lung cancer (Phillips
et al., 2003). The fermentation of disaccharides and the production of
the breath hydrogen was used to investigate lactose malabsorption
(Newcomer et al., 1975). Hydrogen can be detected in the breath using
gas chromatography or an electrochemical cell. This can be minia-
turised to produce a portable, bedside instrument (Lee et al., 2000) but
more recently telemetric capsules have been equipped with gas-sensing
modality (Kalantar-Zadeh et al., 2018).
Since hydrogen can only be produced by bacterial reductive meta-
bolism, this raised interest in the possibility of using the bacteria in the
bowel to indicate the arrival of a test meal in the caecum, to determine
the oro-caecal transit time (OCTT). It was important that the dis-
accharide was not absorbed during its transit through the small in-
testines so that the sharp rise in hydrogen in the breath signalled that
the oro-caecal transit was complete. This remains a methodological
diﬃculty. Rana and Malik summarized the use of hydrogen breath
testing in three conditions: diagnosis of bacterial overgrowth of the
small bowel (includes measurements using glucose); carbohydrate
malabsorption (especially lactose or fructose) and thirdly altered transit
of food through this the stomach and small intestines (Rana and Malik,
2014). In preparation for this test, the patient must not be on anti-
biotics, must refrain from consumption of any interfering slowly di-
gested high-ﬁbre food such as beans and cereals and must fast for 12 h
prior to the test. They also must not smoke as carbon monoxide is
picked up by the hydrogen detector, nor should they exercise before the
test as this reduces breath hydrogen (Braden, 2009).
Measurements of orocaecal transit time (OCTT) show some agree-
ment with other measurement techniques although the endpoints can
be diﬃcult to note in some patients. It is generally shorter than that
measured by scintigraphic techniques with normal values of around
90min in controls (Rana et al., 2008), partly inﬂuenced by the pre-
sentation as a liquid. OCTT has been shown in other work to be delayed
in type I and II diabetes (Rana et al., 2011; Faria et al., 2013). Hydrogen
breath tests have also been used to measure OCTT during various stages
of pregnancy, in tandem with ultrasound to measure gastric emptying
(Chiloiri et al., 2001). In the ultrasound technique, the gastric volume is
calculated from measurements of the longitudinal axis (L), and ante-
roposterior (AP) diameters (the cross-section is an ellipse) and applying
the formula: volume= π/4× L×AP.
Pregnancy is often accompanied by dyspepsia in the ﬁrst trimester,
which was noted in this study although the breath test indicated that
gastric emptying was normal. In the third trimester OCTT was pro-
longed from 80min (interquartile range 50–235.5 min) to 100min
(interquartile range 50.5–240min), returning to 70 (interquartile range
40.5–240min) in the post-partum period.
Unfortunately, there are individuals who do not have a bacterial
population that can produce hydrogen and generate false negatives at a
reported rate of 3–25% (Braden, 2009). These patients may be methane
producers, since the hydrogen is directly incorporated in alkane for-
mation. The alternative [13C]-breath test is a useful solution to the
problem. Carbon 13 is a stable isotope and the additional neutron al-
lows detection of the mass diﬀerence using a mass spectrometer. The
natural abundance of carbon 13 is 1.11% of all carbon atoms and a
wide range of substrates are available. This allows the exploration of
liver and pancreatic function but [13C]-acetate has been widely used in
OCTT measurements in children (Hauser et al., 2006) and [13C]-lactose
ureide in veterinary OCTT studies (Wyse et al., 2004). Hauser and
colleagues established the normal values for the gastric emptying of a
standardized liquid meal in children between 4 and 15 years by com-
bining scintigraphy using [99mTc] technetium-labelled tin colloid with
[13C]-acetate and found a strong correlation. Parker and colleagues
have shown that the incorporation of breath tests markers into complex
matrices generates many problems in data interpretation. The group
compared the use of a [13C]-lipid constituents [13C]-octanoate (OCC),
[13C]-acetate (ACC) and [13C]-trioctanoin (TCC) to measure the gastric
emptying of lipid emulsions in healthy adults. The [13C]-acetate marker
was used as a discriminatory signal since it partitions diﬀerently in fat
compared to the two markers that should have produced similar results
(OCC and TCC). They were unsuccessful due to the interaction of these
markers with the lipid emulsion in the stomach environment, where
protonation occurred and complications due to post-prandial proces-
sing of the TCC in the upper small intestine confounded interpretation
(Parker et al., 2017). The breath test therefore remains of interest but
use tends to be conﬁned to use in groups that are unsuitable for more
invasive tests or those involving radioactive tracers.
5.3.2. Electrical impedance monitoring and Electrogastrography (EGG)
Electrical resistance describes the process where a conductor resists
any current going through opposing electrodes. As resistance decreases,
the lower the voltage needed to sustain a given current ﬂow. Electrical
impedance is a related phenomenon but describes the resistance to
change in voltage. In an electrical circuit, an inductor resists changes in
the current whereas a capacitor resist changes (smooths out) the signal
between electrodes when voltage is altered. From this it is seen that the
basis of an instrument would be to measure the signal propagated
across the electrodes placed opposite and around the circumference of
signals propagated through the body section. It has long been realised
Fig. 11. (a) Correlation between time to maximal dissolved drug concentration in duodenum and time needed to achieve maximal systemic drug concentration
(r=0.98). (■) Fasted state data. (□) Fed state data. (b) Typical example of a second peak in the systemic concentration–time proﬁle for one volunteer (fasted state).
Insert depicts the corresponding dissolved drug concentration in the duodenum as a function of time. Data adopted from Van Den Abeele et al. (2017c).
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that this would be an attractive way to measure the changes in volume
of an object in the body which had a material with a diﬀerent dielectric;
for example, the heart, the lungs and the bladder. By using multiple
electrodes, a tomographic representation can be generated and this
immediately suggested a possible use for measuring gastric emptying.
Potentially such a system would be extremely cheap, portable and
chemical free.
Chang and colleagues described a simple system to measure liquid
gastric emptying in man which had a moderate sensitivity compared to
scintigraphic measurement (Chang et al., 2001). One of the problems is
that high amounts of body fat generates errors and in the Chang study,
only 20/24 of the subjects could be used to generate successful mea-
surements.
This issue obviously leads to clinical under-utilization of EGG and
recently a group in Calgary described a modiﬁcation to enhance the
sensitivity of electrogastrography, albeit at an early stage of develop-
ment. In the study, the use of a miniaturised swallowable electronic
oscillator in an expandable, self-disintegrating object (a pseudo bezoar)
is described (Poscente and Mintchev, 2017). The requirements this test
is that the unit is retained in the stomach for the duration of the test –
essentially a gastroretentive device–which is then disaggregated to
allow smooth movement out of the stomach at the end of the test. This
might be aided by pH shift (administration of an antacid) or hot liquid
to raise lumenal temperature to 45 °C. The electronic oscillator sends
out a single frequency signal which is easily discriminated background
noise by cutaneous electrodes. The authors carried out a study in dogs
before and after the administration of neostigmine to modify motility.
Disintegration of the device was observed but the issue is that the
battery remains intact which authors failed to comment upon.
The measurement of the action of cholinergic agents in pigs was
described by a group in the Czech Republic (Kvetina et al., 2015) using
a commercially available electrogastography system (Medical Mea-
surement Systems B.V.) which is able to amplify and ﬁlter the signal
from background interference of heart rhythms and breathing move-
ments and ultraslow signal to preserve the dominant frequencies of the
EGG signal. An array of seven electrodes to record the EGG and an
abdominal belt to subtract the respiratory signal were positioned on the
underside of the pig abdomen. The system was used by the authors to
measure the eﬀect of basic acetylcholinesterase modulators, atropine
and neostigmine, on porcine EGG.
Overall, this technology has rather limited application in drug de-
livery and is likely to be supplanted by recent advances in point-of-care
ultrasonography (PoCUS).
5.3.3. Ultrasonography
In real-time sonography (RTS), a closely coupled probe placed on
the abdomen generates intermittent sound waves and receives back the
echoes which are digitally processed to provide a black-and-white re-
presentation of the impedance that the wave encounters (see the ex-
cellent review by Abu-Zidan et al., 2011). Reﬂection from a solid object
generates white pixels whereas in ﬂuid ﬁlled compartments, the wave is
propagates forward giving a black echogenic image. The frequency of
the wave determines resolution and depth of penetration. The probe
can also be run in continuous mode to generate Doppler images to study
movement within the structure.
Gastric emptying can be measured by assembling cross sections
across the organ when the stomach is full of liquid; however, if full of
air, measurements become diﬃcult. The location of the stomach when
it is high in the abdomen, with the fundus obscured by the costal
margin, can also frustrate measurement. For this reason, ultrasound
measurements are often restricted to the antrum which is nearly always
visible (Darwiche et al., 1999). Darwiche and colleagues used RTS to
estimate the percentage of a 300mL rice pudding meal in the stomach
of normal controls and diabetic patients. At 15min post-ingestion,
diabetic patients emptied 29% of the test meal versus 63% for the
controls.
Ultrasound has also been used to measure gastric emptying of water
in pregnancy at full term (Wong et al., 2002). The risk of pulmonary
aspiration of stomach contents during anaesthesia at delivery is well
established but rare; it is however a deﬁned risk and before elective
induction; the physicians prefer the stomach to be empty. Antral cross
section measurements were generated and the half-time of gastric
emptying from both ultrasound measurements and serum acet-
aminophen concentrations after administration of 15mL of a liquid
acetamidophen preparation with 50 or 300mL water. Data collected
showed that healthy, full term women, not in labour had unaltered
gastric emptying rates compared to controls.
Bataille and colleagues conducted an ultrasound examination in
women during labour who were receiving epidural anaesthesia and
showed that there was a slowing of emptying in early labour, suggesting
that the risk of aspiration was supported (Bataille et al., 2014). Süm-
pelmann and colleagues have conducted an ultrasound assessment of
healthy pre-school children. The objective here was to assess the fea-
sibility of the ultrasound measurement to measure gastric emptying of
light meals in order to generate protocols to decrease the risk of as-
piration in anaesthesia but allow the children appropriate nutrition
(Sümpelmann et al., 2017).
Critically ill patients may have an issue of retained gastric volume
and ultrasound examination has been used to stratify those patients
who are at risk. The measurement should be quick and simple and often
must be completed at the bedside; the objective is to identify those
patients whose gastric emptying is so slow that they require en-
dotracheal intubation (Hamada et al., 2014). A patient with a full sto-
mach that is emptying slowly with multiple co-morbidities is diﬃcult to
manage and is a leading cause of death in anaesthesia -associated as-
piration. Semplemann and colleagues report on an ultrasound in-
vestigation of a 48y patient using a procedure that has found wide use
clinically - PoCUS. Gastric point-of-care ultrasound. This was used to
assess the emptying of the stomach following infusion of a prokinetic -
erythromycin at 3mg kg-1 and conﬁrmation of gastric emptying prior to
surgery (Sebrechts et al., 2018).
Since 2010, ultrasound devices based on portable devices including
attachments for mobile phones have interested researchers and health-
curious individuals. The fabrication of cheap robust capacitive trans-
ducers as an alternative to piezo-electric elements was described in
2018 (Gerardo et al., 2018) and is likely to result in a new generation of
medical apps on smartphones. Very recently, the Butterﬂy IQ handheld
ultrasound set has been launched after raising $250 million from an
investment syndicate. The probe connects to a phone or iPad as the
reporting/recording device. These highly mobile instruments have an
obvious place in medicine and medical journals are now reporting the
deliberations of experts establishing recommendations for training and
interpretation of data (Diprose et al., 2017; Cardim et al., 2018).
Finally, we consider methods to explore regional absorption and
trek back towards an in vitro system that is able to capture mechanistic
information that may be unavailable from clinical studies.
6. In vitro/in silico methods to evaluate regional drug absorption
Knowledge of regional changes in the properties of the gastro-
intestinal tract are an essential component of mechanistic models to
predict drug absorption and are particularly important to guide devel-
opment of controlled release dosage forms. Primary determinants of
regional absorption are regional changes in solubility and permeability.
The solubility of a drug in diﬀerent portions of the gastrointestinal tract
might vary due to changes in pH, buﬀer capacity, surfactant con-
centration, ﬂuid volume and viscosity. However, the solubility changes
are not common across all drugs but are dependent on speciﬁc drug
properties. For example, the regional luminal solubility of the neutral
molecule prednisolone, does not vary signiﬁcantly while mesalamine, a
zwitterion, shows increasing solubility down the GI tract. To guide
development of a drug product, knowledge of regional variation in
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solubility can be important but measurement in aspirated luminal ﬂuids
is not always convenient. In more practical terms, the use of biorelevant
media simulating the in vivo situation such as FaSSGF and FeSSGF
which simulate the fasted and fed state stomach respectively, while
FaSSIF and FeSSIF media can be used for the upper small intestine
(Jantratid et al., 2008). Diﬀerent levels of biorelevant media have been
deﬁned with Level I media reﬂecting luminal pH and buﬀer capacity
whereas Level II also take bile acid content, digestion products, and
osmolality of luminal contents into account (Markopoulos et al.,
2015a). In addition, media simulating human colonic ﬂuids have been
developed and were evaluated by measuring solubilities for ketocona-
zole, danazol and felodipine which was compared with measurements
in sampled human colonic ﬂuids (Vertzoni et al., 2010). Composition of
media simulating the distal ileum (SIFileum), ascending colon in the
fasted state (FaSSCoF) and in the fed state (FeSSCoF) have been deﬁned
(Vertzoni et al., 2010; Markopoulos et al., 2015b). These region speciﬁc
biorelevant media are now standardized, commercially available and
widely used across laboratories to generate data as input to physiolo-
gically based absorption models. However, there is still need for more
veriﬁcation of their utility to predict clinical performance with diﬀerent
drugs and formulations. Furthermore, more consideration of the time-
dependency of solubilization is needed. This has already been initiated
for media simulating conditions in the proximal GI tract (Jantratid
et al., 2008) but obviously should apply to other regions as well.
Permeability is also a key determinant of regional absorption. The
Ussing chamber is a well-established in vitro tool which has been ap-
plied to measure regional permeability in sections taken from duo-
denum, jejunum, ileum and colon which are mounted to allow access to
acceptor and donor compartments. Overall highly permeable com-
pounds show similar Papp in the colon as in the small intestinal seg-
ments, while a lower Papp in colon is seen for more polar compounds
(Sjoberg et al., 2013; Haslam et al., 2011; Rozehnal et al., 2012).
Transporter-mediated uptake or eﬄux as well as intestinal metabolism
can also be demonstrated using tissue samples mounted in the Ussing
chamber. Overall, the research on regional permeability changes still
has many gaps to ﬁll. Data on intestinal transporter protein expression
has started to emerge (Harwood et al., 2015) and the technology for
measurement advances rapidly (Nakamura et al., 2016). However,
comparability of data from diﬀerent laboratories still needs to be con-
ﬁrmed as does the successful integration of expression data into phy-
siologically based models for prediction of the eﬀect on drug regional
absorption.
Aside from solubility and permeability, regional dependent tools to
estimate dissolution and precipitation are important. Various in vitro
tools to study dissolution in the stomach and upper small intestine have
been described (Kourentas et al., 2016) and recently, a two-stage single-
compartment in vitro dissolution test for distal ileum and proximal
colon was proposed based on commercially available setups
(Markopoulos et al., 2015b). Data generated in this system were input
to a PBPK model and simulations were shown to agree with clinical data
for two immediate release highly dosed compounds as well as for one
colon targeting product (Markopoulos et al., 2015b; Georgaka et al.,
2017). Tools for precipitation were recently reviewed (O'Dwyer et al.,
2019).
Regional dependent solubility and permeability measurements
along the length of the human gastrointestinal tract are challenging to
obtain for most drugs and so there have been eﬀorts to develop in silico
models to predict these properties. For solubility, PBPK absorption
models have implemented approaches which attempt to predict solu-
bility throughout the GI tract based on a limited set of measured data
and knowledge of the variation of luminal ﬂuids (Parrott et al., 2009;
Patel et al., 2014; Sjögren et al., 2013). Generally, these models esti-
mate the eﬀect of ionization on solubility based on a drugs pKa values
and knowledge of variation in regional pH, while, for lipophilic mole-
cules where bile salts are important for solubilization, models estimate
regional solubility based on regional bile salt concentrations and a
compound speciﬁc bile salt solubilization ratio. This ratio is generally
estimated based on the compound lipophilicity (Mithani et al., 1996) or
from measurements made in media containing a known concentrations
of bile salts.
Physiologically based absorption models have also implemented
predictive models to estimate regional permeabilities. Typically, per-
meability is measured in an in vitro experiment and this value is then
transformed to an estimate of in vivo jejunal permeability based on a
correlation built for a set of reference drugs where permeability has
been measured. Regional permeability changes may then be scaled
based on knowledge of the changing surface area due to diﬀerent gut
dimensions, intestinal folding and the density of villi and microvilli
(Olivares-Morales et al., 2015). Some in silico models also attempt to
account for the changing mixture of transcellular and paracellular
transport in diﬀerent regions as well as the eﬀect on permeability of
varying drug ionization due to diﬀerent regional pH. These more
complex mechanistic models are challenging to parameterize and verify
and some commercial PBPK tools include empirical Absorption Scale
Factors optimized so that simulations best match measured human
absorption data for a set of reference drugs (Parrott and Lave, 2010).
Overall there is great potential for physiologically based models to
leverage knowledge of regional absorption changes to optimize clinical
formulation development. Achievement of this potential will require
further research to develop predictive in vitro tools and importantly the
veriﬁcation that data generated with these tools translates to clinical
performance.
7. Conclusions
The impact of regional diﬀerences in anatomy and physiology along
the gastrointestinal tract on the absorption of drugs is profound and for
some classes of active pharmaceutical ingredients, notably small orally-
administered biologics such as desmopressin or cyclosporin, the chal-
lenge of understanding the nature of the barriers is daunting. In these
investigations, the integration of knowledge requires an appreciation of
events at the cellular level: examining the ﬂux of drug molecules
through the absorbing membranes of diﬀerent regions of the gut with
those aspects of formulation which are inﬂuenced by motility and in-
teraction with food at the macro scale. Pharmaceutical scientists are
great ‘adopters’ of clinical and chemical technology and progress in
optimisation of dosage form has borrowed heavily from clinical ima-
ging disciplines as noted in this review. A next generation of imaging
devices and technologies based on smart-phone add-ons might lead us
to new possibilities for looking at regional drug absorption in special
groups, within their home locations, including the young and the el-
derly.
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